The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tanezumab for OA Pain

Tanezumab for OA Pain

February 21, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Tanezumab is an investigational humanized monoclonal antibody that selectively targets, binds to and inhibits nerve growth factor. In the body, nerve growth factor levels increase due to inflammation, injury or chronic pain states. Tanezumab’s mechanism differs from opioids and other analgesics and has not demonstrated a risk for addiction, misuse or dependence to date.

You Might Also Like
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
  • Pfizer-Lilly Pain Drug Meets Late-Stage Trial Goals
  • Lilly Says New Type of Pain Drug Could Reduce Need for Opioids
Also By This Author
  • Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

During a phase 3 study, researchers evaluated the efficacy and safety of subcutaneous tanezumab vs. placebo in 849 adults with moderate to severe pain from knee or hip osteoarthritis (OA).1 The study was a randomized, double-blind, placebo-controlled, multi-center, parallel-group, 24-week clinical trial. To participate, patients had to have an average OA duration of more than six years. Additionally, they had to have inadequate pain relief from or be intolerant to at least three different classes of analgesics. At the start of the study, patients reported the effects of pain on their everyday functionality.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients were randomized into three treatment groups, which received three injections of either 2.5 mg of tanezumab, 5 mg of tanezumab or placebo every eight weeks. The efficacy of tanezumab compared with placebo was measured by changes from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale, the WOMAC Physical Function subscale and the patient’s Global Assessment of OA at 24 weeks. The study also included a 24-week safety follow-up.

At Week 24, patients treated with 2.5 mg of tanezumab met two of the three primary efficacy endpoints compared with placebo-treated patients. Patients who were treated with 5 mg of tanezumab met all three primary endpoints, demonstrating statistically significant improvements in physical function, pain and overall assessment of OA compared with placebo-treated patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

During the study, one osteonecrosis event and one subchondral insufficiency fracture occurred in tanezumab-treated patients. Placebo-treated patients experienced no adverse events. The detailed safety and efficacy data from this study will be reported at a later date.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Pfizer Inc. News release: Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain. 2019 Jan 29.

Filed Under: Analgesics, Drug Updates

You Might Also Like:
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
  • Pfizer-Lilly Pain Drug Meets Late-Stage Trial Goals
  • Lilly Says New Type of Pain Drug Could Reduce Need for Opioids
  • Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.